A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome
Authors:
- Valentina MercurioVMValentina Mercurio
- Antonio RuvoloARAntonio Ruvolo
- Concetta PirozziCPConcetta Pirozzi
- Filomena MicilloFMFilomena Micillo
- Guido CarlomagnoGCGuido Carlomagno
- Fabrizia GriecoFGFabrizia Grieco
- Serafino FazioSFSerafino Fazio
Open Access
- 1 January 2012
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Cardiology
- Vol. 4 (3) , 77-83
Abstract
To test the efficacy of a proprietary nutraceutical combination in reducing insulin resistance associated with the metabolic syndrome (MetS). Sixty-four patients with MetS followed at a tertiary outpatient clinic were randomly assigned to receive either placebo or a proprietary nutraceutical combination (AP) consisting of berberine, policosanol and red yeast rice, in a prospective, double-blind, placebo-controlled study. Evaluations were performed at baseline and after 18 wk of treatment. The homeostasis model assessment of insulin resistance (HOMA-IR) index was the primary outcome measure. Secondary endpoints included lipid panel, blood glucose and insulin fasting, after a standard mixed meal and after an oral glucose tolerance test (OGTT), flow-mediated dilation (FMD), and waist circumference. Fifty nine patients completed the study, 2 withdrew because of adverse effects. After 18 wk there was a significant reduction in the HOMA-IR index in the AP group compared with placebo (ΔHOMA respectively -0.6 ± 1.2 vs 0.4 ± 1.9; P < 0.05). Total and low density lipoprotein cholesterol also significantly decreased in the treatment arm compared with placebo (Δlow density lipoprotein cholesterol -0.82 ± 0.68 vs -0.13 ± 0.55 mmol/L; P < 0.001), while triglycerides, high density lipoprotein cholesterol, and the OGTT were not affected. In addition, there were significant reductions in blood glucose and insulin after the standard mixed meal, as well as an increase in FMD (ΔFMD 1.9 ± 4.2 vs 0 ± 1.9 %; P < 0.05) and a significant reduction in arterial systolic blood pressure in the AP arm. This short-term study shows that AP has relevant beneficial effects on insulin resistance and many other components of MetS.Keywords
This publication has 23 references indexed in Scilit:
- Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthaseCardiovascular Research, 2009
- The Metabolic SyndromeEndocrine Reviews, 2008
- Berberine-Induced Upregulation of Circulating Endothelial Progenitor Cells Is Related to Nitric Oxide Production in Healthy SubjectsCardiology, 2008
- Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid BerberineThe Journal of Clinical Endocrinology & Metabolism, 2008
- Insulin Resistance as Estimated by Homeostasis Model Assessment Predicts Incident Symptomatic Cardiovascular Disease in Caucasian Subjects From the General PopulationDiabetes Care, 2007
- Eulipidemic Effects of Berberine Administered Alone or in Combination with Other Natural Cholesterol-lowering AgentsArzneimittelforschung, 2007
- The metabolic syndromeThe Lancet, 2005
- Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statinsNature Medicine, 2004
- The Antihyperglycaemic Activity of Berberine Arises from a Decrease of Glucose AbsorptionPlanta Medica, 2003
- Homeostasis Model Assessment of Insulin Resistance in Relation to the Incidence of Cardiovascular DiseaseDiabetes Care, 2002